[1]
Gordon, K., Papp, K., Gooderham, M., Morita, A., Foley, P., Tha?i, D., Kundu, S., Kisa, R., Wei, L. and Banergee, S. 2020. BMS-986165, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor: Evaluation of Changes in Laboratory Parameters in Response to Treatment in a Phase 2 Trial in Psoriasis Patients. SKIN The Journal of Cutaneous Medicine. 4, 5 (Sep. 2020), s28. DOI:https://doi.org/10.25251/skin.4.supp.28.